Galina Snigireva
Galina Snigireva has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Marina Vladimirovna Ryzhova
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
7 shared publications - Ekaterina Nikolaevna Telysheva
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
6 shared publications - E. G. Shaikhaev
Burdenko Neurosurgical Center
5 shared publications - Olga G. Zheludkova
V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children
4 shared publications - Sergey K. Gorelyshev
Burdenko Neurosurgical Center
3 shared publications - Suzanna Andranikovna Galstyan
N.N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of Russia
3 shared publications
Latest Publications
- 25 May 2026
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 90 (3) , 80-85
Breast cancer metastasis to parasagittal meningioma: a case report and literature review
Introduction. Tumor-to-tumor metastasis is a rare phenomenon, and meningiomas are the most frequent recipient in these cases. The most common donor tumors are breast and lung cancers. Objective. To describe a rare clinical case of breast adenocarcinoma metastasis to meningioma, problems of diagnosis and treatment. Material and methods. A 67-year-old patient presented with breast cancer. Neuroimaging revealed parasagittal intracranial tumor. Resection of tumor was followed by histological and immunohistochemical examination of specimens. There was postoperative radiotherapy (CyberKnife). The authors present a rare case of breast cancer metastasis to parasagittal meningioma and reviewed 152 available cases in the literature. Results. Histological examination revealed two components: benign transitional meningioma (Grade I) and invasive breast adenocarcinoma metastasis (positive expression of AE1/AE3 CK). Tumor stabilization was achieved after resection and subsequent radiotherapy. Conclusion. This rare case demonstrates the need for a more detailed neuroradiological examination in patients with previously diagnosed malignancies referred for surgical treatment of intracranial meningiomas.
- 25 May 2026
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 90 (3) , 80-85
Breast cancer metastasis to parasagittal meningioma: a case report and literature review
Introduction. Tumor-to-tumor metastasis is a rare phenomenon, and meningiomas are the most frequent recipient in these cases. The most common donor tumors are breast and lung cancers. Objective. To describe a rare clinical case of breast adenocarcinoma metastasis to meningioma, problems of diagnosis and treatment. Material and methods. A 67-year-old patient presented with breast cancer. Neuroimaging revealed parasagittal intracranial tumor. Resection of tumor was followed by histological and immunohistochemical examination of specimens. There was postoperative radiotherapy (CyberKnife). The authors present a rare case of breast cancer metastasis to parasagittal meningioma and reviewed 152 available cases in the literature. Results. Histological examination revealed two components: benign transitional meningioma (Grade I) and invasive breast adenocarcinoma metastasis (positive expression of AE1/AE3 CK). Tumor stabilization was achieved after resection and subsequent radiotherapy. Conclusion. This rare case demonstrates the need for a more detailed neuroradiological examination in patients with previously diagnosed malignancies referred for surgical treatment of intracranial meningiomas.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 63-79
Gliomas and glioneuronal tumors in children. Interpretation of molecular features
This review consolidates current knowledge on genetic alterations observed in pediatric glial and glioneuronal tumors of the central nervous system (CNS). Some of these alterations serve as diagnostic biomarkers, whereas others may inform the selection of targeted therapeutic strategies. Drawing on both diagnostic and clinical perspectives, the authors aim to facilitate a more comprehensive understanding of the WHO Classification of CNS Tumors and to promote interdisciplinary collaboration. This resource is intended to support accurate tumor classification, guide molecular testing, and aid in identifying actionable genetic targets. The content may be of practical value to pediatric neuro-oncologists, molecular pathologists, neuropathologists, and researchers involved in CNS tumor diagnostics and treatment. For user convenience, selected data are summarized in tables.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 63-79
Open AccessGliomas and glioneuronal tumors in children. Interpretation of molecular features
This review consolidates current knowledge on genetic alterations observed in pediatric glial and glioneuronal tumors of the central nervous system (CNS). Some of these alterations serve as diagnostic biomarkers, whereas others may inform the selection of targeted therapeutic strategies. Drawing on both diagnostic and clinical perspectives, the authors aim to facilitate a more comprehensive understanding of the WHO Classification of CNS Tumors and to promote interdisciplinary collaboration. This resource is intended to support accurate tumor classification, guide molecular testing, and aid in identifying actionable genetic targets. The content may be of practical value to pediatric neuro-oncologists, molecular pathologists, neuropathologists, and researchers involved in CNS tumor diagnostics and treatment. For user convenience, selected data are summarized in tables.
- 6 December 2023
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 87 (6) , 14-24
Chordoid gliomas of the third ventricle
Background. Chordoid glioma is a rare slow-growing tumor of the central nervous system. Available world experience includes no more than 200 cases (lesion of the third ventricle in absolute majority of cases). Recognition and treatment of chordoid glioma are currently difficult problems due to small incidence of this disease. Objective. To describe clinical manifestations and surgical treatment of chordoid glioma of the third ventricle considering literature data and own experience. Material and methods. There were 12 patients (6 men and 6 women) with chordoid glioma between 2004 and 2023 (10 patients with lesion of the third ventricle, 1 — lateral ventricle, 1 — pineal region). Only patients with tumors of the third ventricle were analyzed. Results. Total and subtotal resection was performed in 1 and 3 cases, respectively. Five patients underwent partial resection, 1 patient underwent biopsy. The follow-up data were available in 7 out of 10 patients (mean 25 months). Radiotherapy was performed in 4 patients (continued tumor growth in 2 cases). One patient died. Conclusion. Chordoid glioma is a benign tumor predominantly localized in the third ventricle. Preoperative MRI and CT in some cases make it possible to suspect chordoid glioma and differentiate this tumor from craniopharyngioma, meningioma and pituitary adenoma by such signs as isointense signal in T1WI, hyper- or isointense signal in T2WI, homogeneous contrast enhancement and edema of basal ganglia in T2 FLAIR images. The only effective treatment for chordoid glioma is surgery. Total resection is often impossible or extremely dangerous due to location of tumor, large size and invasion of the third ventricle. Postoperative mental disorders and diabetes insipidus, including severe hypernatremia, are common that requires mandatory monitoring of water and electrolyte balance.
- 6 December 2023
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 87 (6) , 14-24
Chordoid gliomas of the third ventricle
Background. Chordoid glioma is a rare slow-growing tumor of the central nervous system. Available world experience includes no more than 200 cases (lesion of the third ventricle in absolute majority of cases). Recognition and treatment of chordoid glioma are currently difficult problems due to small incidence of this disease. Objective. To describe clinical manifestations and surgical treatment of chordoid glioma of the third ventricle considering literature data and own experience. Material and methods. There were 12 patients (6 men and 6 women) with chordoid glioma between 2004 and 2023 (10 patients with lesion of the third ventricle, 1 — lateral ventricle, 1 — pineal region). Only patients with tumors of the third ventricle were analyzed. Results. Total and subtotal resection was performed in 1 and 3 cases, respectively. Five patients underwent partial resection, 1 patient underwent biopsy. The follow-up data were available in 7 out of 10 patients (mean 25 months). Radiotherapy was performed in 4 patients (continued tumor growth in 2 cases). One patient died. Conclusion. Chordoid glioma is a benign tumor predominantly localized in the third ventricle. Preoperative MRI and CT in some cases make it possible to suspect chordoid glioma and differentiate this tumor from craniopharyngioma, meningioma and pituitary adenoma by such signs as isointense signal in T1WI, hyper- or isointense signal in T2WI, homogeneous contrast enhancement and edema of basal ganglia in T2 FLAIR images. The only effective treatment for chordoid glioma is surgery. Total resection is often impossible or extremely dangerous due to location of tumor, large size and invasion of the third ventricle. Postoperative mental disorders and diabetes insipidus, including severe hypernatremia, are common that requires mandatory monitoring of water and electrolyte balance.
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 85 (3) , 5-11
Verification of the diagnosis of supratentorial ependymomas by real-time PCR
Дифференциальная диагностика супратенториальных эпендимом представляет особую сложность в нейроонкологии ввиду неспецифических клинических и рентгенологических данных, редко встречающейся «классической» морфологической картины, а также неспецифического иммунофенотипа. Благодаря молекулярно-генетическим методам, в частности ПЦР в режиме реального времени, стало возможно верифицировать супратенториальные эпендимомы и идентифицировать их молекулярную группу, от которой зависит дальнейший прогноз. ЦЕЛЬ ИССЛЕДОВАНИЯ Разработать комплекс молекулярно-генетических тестов на основе ПЦР в режиме реального времени, позволяющий верифицировать супратенториальные эпендимомы. МАТЕРИАЛ И МЕТОДЫ Для данного исследования были отобраны 56 образцов опухолевой ткани от пациентов с супратенториально локализованной эпендимомой, WHO Grade II, и анапластической эпендимомой, WHO Grade III. Для диагностики методом ПЦР в режиме реального времени мы разработали праймеры и флюоресцентные TaqMan-зонды для детекции слияний генов ZFTA::RELA, ZFTA::MAML2, ZFTA::NCOA2, ZFTA::MAML3, YAP1::MAMLD1 и YAP1::FAM118B. Для иммуногистохимического исследования использовали моноклональные кроличьи антитела анти-NF-kb p65 (HUABIO, Китай), исследование проводили на иммуностейнере AutostainerLink 48 (DAKO, Дания). РЕЗУЛЬТАТЫ Методом ПЦР в режиме реального времени удалось верифицировать диагноз для 69,9% (n=39) образцов и классифицировать их на молекулярные группы ZFTA- или YAP1-позитивных супратенториальных эпендимом. Иммуногистохимически удалось верифицировать 58% (n=29) эпендимом. ЗАКЛЮЧЕНИЕ Диагностика методом ПЦР в режиме реального времени — сравнительно быстрый, доступный и легко интерпретируемый метод, позволяющий верифицировать молекулярную группу в 70% случаев супратенториальных эпендимом без применения дополнительных методов.
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 85 (3) , 5-11
Verification of the diagnosis of supratentorial ependymomas by real-time PCR
Дифференциальная диагностика супратенториальных эпендимом представляет особую сложность в нейроонкологии ввиду неспецифических клинических и рентгенологических данных, редко встречающейся «классической» морфологической картины, а также неспецифического иммунофенотипа. Благодаря молекулярно-генетическим методам, в частности ПЦР в режиме реального времени, стало возможно верифицировать супратенториальные эпендимомы и идентифицировать их молекулярную группу, от которой зависит дальнейший прогноз. ЦЕЛЬ ИССЛЕДОВАНИЯ Разработать комплекс молекулярно-генетических тестов на основе ПЦР в режиме реального времени, позволяющий верифицировать супратенториальные эпендимомы. МАТЕРИАЛ И МЕТОДЫ Для данного исследования были отобраны 56 образцов опухолевой ткани от пациентов с супратенториально локализованной эпендимомой, WHO Grade II, и анапластической эпендимомой, WHO Grade III. Для диагностики методом ПЦР в режиме реального времени мы разработали праймеры и флюоресцентные TaqMan-зонды для детекции слияний генов ZFTA::RELA, ZFTA::MAML2, ZFTA::NCOA2, ZFTA::MAML3, YAP1::MAMLD1 и YAP1::FAM118B. Для иммуногистохимического исследования использовали моноклональные кроличьи антитела анти-NF-kb p65 (HUABIO, Китай), исследование проводили на иммуностейнере AutostainerLink 48 (DAKO, Дания). РЕЗУЛЬТАТЫ Методом ПЦР в режиме реального времени удалось верифицировать диагноз для 69,9% (n=39) образцов и классифицировать их на молекулярные группы ZFTA- или YAP1-позитивных супратенториальных эпендимом. Иммуногистохимически удалось верифицировать 58% (n=29) эпендимом. ЗАКЛЮЧЕНИЕ Диагностика методом ПЦР в режиме реального времени — сравнительно быстрый, доступный и легко интерпретируемый метод, позволяющий верифицировать молекулярную группу в 70% случаев супратенториальных эпендимом без применения дополнительных методов.
- 14 February 2023
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 85 (1) , 51-56
Astrocytoma with 1p19q codeletion
На примере рецидивирующей опухоли с 10-летним катамнезом авторы показывают, что мутация генов IDH1/2 в астроцитомах не всегда является ранним событием в патогенезе глиомы, в редких случаях в астроцитомах может быть найдена коделеция 1p19q и IDH-мутантные опухоли могут возникать в детском возрасте.
- 14 February 2023
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 85 (1) , 51-56
Astrocytoma with 1p19q codeletion
На примере рецидивирующей опухоли с 10-летним катамнезом авторы показывают, что мутация генов IDH1/2 в астроцитомах не всегда является ранним событием в патогенезе глиомы, в редких случаях в астроцитомах может быть найдена коделеция 1p19q и IDH-мутантные опухоли могут возникать в детском возрасте.
- Open Access
- 3 March 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 47-56
Mutational profile of KRAS-positive colorectal cancer
Aim: to study the features of the molecular genetic profile of KRAS-positive colorectal cancer (CRC).Material and Methods. The study included 42 patients diagnosed with colorectal cancer. The KRAS gene mutation was detected in tumor tissue of these patients by real-time PC R. Using the next generation sequencing technology (NGS ) on the Illumina platform, the genes involved in the molecular pathogenesis of colorectal cancer, namely KRAS, BRAF, NRAS, APC, TP53, SMAD2, SMAD4, FBXW7, PIK3CA, CTNNB1, TCF7L2, MLH1, MSH2, MSH3, MSH6, ATM, TGF-BR2, AKT1, CDC27, CASP8, MAP2K4, DCC, DMD, MAP7, ERBB2, P3H3, MIER3, CADM1, FLT4, PTPN12, PIK3R1, and EP300 were analyzed. Sample preparation of libraries from isolated DNA was carried out using commercial kits GeneRead DNAS eq Targeted Panel v2 Human Colorectal Cancer (Qiagen, USA ); NEBNext Ultra DNA library Prep kit for Illumina and NEBNext Multiplex Oligos for Illumina (New England BioLabs).Results. In 36 patients with KRAS-positive tumors, changes were observed in 13 genes involved in the molecular pathogenesis of colorectal cancer. A total of 82 somatic variants were identified. Moreover, 9 patients additionally had one mutation each, 17 patients had 2 mutations each, 7 patients had 3 mutations each, and 3 patients had 4 mutations each. Combination of three mutations in key genes involved in the pathogenesis of colorectal cancer (KRAS, APC и TP53) was detected in 15 (36 %) patients. Combination of two mutations in the KRAS and APC genes was detected in 10 (23.8 %) patients, and in the KRAS and TP53 genes – in 8 (19.1 %) patients. The largest number of somatic mutations was found in the APC (59.5 %) and TP53 (54.7 %) genes. It was hown that a combination of three mutations in key genes was the most unfavorable prognosis factor and indicated a higher aggressiveness of the tumor process.Conclusion. The information obtained using the NGS method on the mutational status of a KRAS -positive tumor in patients with colorectal cancer allows for personalized treatment as well as predicting the outcome.
- 3 March 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 47-56
Open AccessMutational profile of KRAS-positive colorectal cancer
Aim: to study the features of the molecular genetic profile of KRAS-positive colorectal cancer (CRC).Material and Methods. The study included 42 patients diagnosed with colorectal cancer. The KRAS gene mutation was detected in tumor tissue of these patients by real-time PC R. Using the next generation sequencing technology (NGS ) on the Illumina platform, the genes involved in the molecular pathogenesis of colorectal cancer, namely KRAS, BRAF, NRAS, APC, TP53, SMAD2, SMAD4, FBXW7, PIK3CA, CTNNB1, TCF7L2, MLH1, MSH2, MSH3, MSH6, ATM, TGF-BR2, AKT1, CDC27, CASP8, MAP2K4, DCC, DMD, MAP7, ERBB2, P3H3, MIER3, CADM1, FLT4, PTPN12, PIK3R1, and EP300 were analyzed. Sample preparation of libraries from isolated DNA was carried out using commercial kits GeneRead DNAS eq Targeted Panel v2 Human Colorectal Cancer (Qiagen, USA ); NEBNext Ultra DNA library Prep kit for Illumina and NEBNext Multiplex Oligos for Illumina (New England BioLabs).Results. In 36 patients with KRAS-positive tumors, changes were observed in 13 genes involved in the molecular pathogenesis of colorectal cancer. A total of 82 somatic variants were identified. Moreover, 9 patients additionally had one mutation each, 17 patients had 2 mutations each, 7 patients had 3 mutations each, and 3 patients had 4 mutations each. Combination of three mutations in key genes involved in the pathogenesis of colorectal cancer (KRAS, APC и TP53) was detected in 15 (36 %) patients. Combination of two mutations in the KRAS and APC genes was detected in 10 (23.8 %) patients, and in the KRAS and TP53 genes – in 8 (19.1 %) patients. The largest number of somatic mutations was found in the APC (59.5 %) and TP53 (54.7 %) genes. It was hown that a combination of three mutations in key genes was the most unfavorable prognosis factor and indicated a higher aggressiveness of the tumor process.Conclusion. The information obtained using the NGS method on the mutational status of a KRAS -positive tumor in patients with colorectal cancer allows for personalized treatment as well as predicting the outcome.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 84 (3) , 40-47
Sarcomas of the central nervous systems. Clinical observations
Представлены 3 случая редких сарком ЦНС: две CIC-саркомы и одна DICER1-саркома. Опухоли были исследованы с помощью метода анализа структуры метилирования ДНК. Важно помнить, что первичные саркомы могут возникать в ЦНС и включать в перечень дифференциальной диагностики злокачественных опухолей исследования слияний CIC и мутации DICER1.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 84 (3) , 40-47
Sarcomas of the central nervous systems. Clinical observations
Представлены 3 случая редких сарком ЦНС: две CIC-саркомы и одна DICER1-саркома. Опухоли были исследованы с помощью метода анализа структуры метилирования ДНК. Важно помнить, что первичные саркомы могут возникать в ЦНС и включать в перечень дифференциальной диагностики злокачественных опухолей исследования слияний CIC и мутации DICER1.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 84 (5) , 40-42
Novel BRAF::EPB41L2 gene fusion in posterior fossa pilocytic astrocytoma. Brief communication
Выявление определенных нарушений в опухолях (как правило, это мутации или слияния генов) позволяет назначать таргетные препараты второй линии терапии или в некоторых случаях при неоперабельных опухолях наблюдать не только постепенный частичный ответ опухоли на лечение, но и вывод этих пациентов из категории инкурабельных. В статье авторы рассказывают о новом редком типе слияния генов BRAF::EPB41L2, выявленном в пилоидной астроцитоме, развившейся в задней черепной ямке у 11-летнего мальчика.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 84 (5) , 40-42
Novel BRAF::EPB41L2 gene fusion in posterior fossa pilocytic astrocytoma. Brief communication
Выявление определенных нарушений в опухолях (как правило, это мутации или слияния генов) позволяет назначать таргетные препараты второй линии терапии или в некоторых случаях при неоперабельных опухолях наблюдать не только постепенный частичный ответ опухоли на лечение, но и вывод этих пациентов из категории инкурабельных. В статье авторы рассказывают о новом редком типе слияния генов BRAF::EPB41L2, выявленном в пилоидной астроцитоме, развившейся в задней черепной ямке у 11-летнего мальчика.
- Open Access
- 17 February 2020
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 65 (6) , 400-407
The possibility of using freely circulating DNA blood plasma in preoperative diagnosis of thyroid tumors
Background: The feasibility of using molecular genetic markers for the diagnosis of thyroid tumors and the impact on the prognosis of thyroid cancer are being actively investigated. The most interesting are genes, the detection of which is associated not only with thyroid cancer, but also with a more aggressive course of the disease. The ability to diagnose the molecular profile of minimally invasive methods with the study of freely circulating DNA tumor tissue in blood plasma is a modern trend of medicine. Aims: to evaluate the frequency of somatic mutations in the "hot spots" of BRAF, KRAS, KRAS, EIF1AX and TERT genes in circulating DNA of blood plasma. Materials and methods: Samples of DNA, extracted from the removed tumor and non-tumor thyroid tissue, were tested for the presence of somatic mutations in hot spots of the genes BRAF, KRAS, NRAS, TERT, and EIF1AX and then in identifying mutations and testing appropriate samples of free circulating DNA in blood plasma. Results: mutations in the" hot spots "of the BRAF gene (exon 15, codon area 600-601) were found in 54 patients, mutations in the" hot spots " of the NRAS gene (exon 3, codon 61) in 12 patients; mutations in the hot spots of the KRAS, TERT and EIF1AX genes were not detected. In freely circulating blood plasma DNA, BRAF gene mutations were detected in 1 case, NRAS gene mutations were detected in 1 case. Conclusions: the use of freely circulating DNA of blood plasma in the testing of the studied sample did not show the feasibility for the diagnosis of thyroid tumors.
- 17 February 2020
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 65 (6) , 400-407
Open AccessThe possibility of using freely circulating DNA blood plasma in preoperative diagnosis of thyroid tumors
Background: The feasibility of using molecular genetic markers for the diagnosis of thyroid tumors and the impact on the prognosis of thyroid cancer are being actively investigated. The most interesting are genes, the detection of which is associated not only with thyroid cancer, but also with a more aggressive course of the disease. The ability to diagnose the molecular profile of minimally invasive methods with the study of freely circulating DNA tumor tissue in blood plasma is a modern trend of medicine. Aims: to evaluate the frequency of somatic mutations in the "hot spots" of BRAF, KRAS, KRAS, EIF1AX and TERT genes in circulating DNA of blood plasma. Materials and methods: Samples of DNA, extracted from the removed tumor and non-tumor thyroid tissue, were tested for the presence of somatic mutations in hot spots of the genes BRAF, KRAS, NRAS, TERT, and EIF1AX and then in identifying mutations and testing appropriate samples of free circulating DNA in blood plasma. Results: mutations in the" hot spots "of the BRAF gene (exon 15, codon area 600-601) were found in 54 patients, mutations in the" hot spots " of the NRAS gene (exon 3, codon 61) in 12 patients; mutations in the hot spots of the KRAS, TERT and EIF1AX genes were not detected. In freely circulating blood plasma DNA, BRAF gene mutations were detected in 1 case, NRAS gene mutations were detected in 1 case. Conclusions: the use of freely circulating DNA of blood plasma in the testing of the studied sample did not show the feasibility for the diagnosis of thyroid tumors.